receptor VEGF receptor 2 (VEGFR2; Simons, Gordon, & Claesson-Welsh, 2016) . VEGF-A is an anti-parallel, disulphide-linked homodimer that binds across immunoglobulin-like domains 2 and 3 of VEGFR2 (Ruch, Skiniotis, Steinmetz, Walz, & Ballmer-Hofer, 2007) . Ligand binding leads to VEGFR2 dimerisation and conformational changes that enable the auto-and transphosphorylation of intracellular tyrosine residues. The recruitment of adaptor proteins to VEGFR2 and subsequent initiation of signalling cascades then lead to cell proliferation, migration, and vascular permeability (Koch, Tugues, Li, Gualandi, & Claesson-Welsh, 2011; Simons et al., 2016) . VEGFR2 can internalise in the presence or absence of ligand stimulation (Ewan et al., 2006; Jopling et al., 2009; Jopling, Howell, Gamper, & Ponnambalam, 2011) .
Through both clathrin-dependent and clathrin-independent mechanisms (Basagiannis et al., 2016) , VEGFR2 first accumulates in Rab5+/EEA1+ endosomes (Gampel et al., 2006) . VEGFR2 can then recycle back to the plasma membrane via short loop Rab4+ endosomes or long loop Rab11+ endosomes (Jopling et al., 2014) , or receptor ubiquitination can initiate lysosomal degradation .
Alternative mRNA splicing of the Vegfa gene leads to a number of endogenous VEGF-A isoforms of varying length, such as "prototypical" VEGF 165 a or VEGF 121 a, as well as variants (e.g., VEGF 165 b) that have distinct carboxy-terminus substitutions of exon 8a for exon 8b (Peach, Mignone, et al., 2018; Woolard et al., 2004) . Additionally, programmed translational readthrough can lead to VEGFAx, an isoform containing both exon 8a-and 8b-encoded residues (Eswarappa et al., 2014) . The residues present within each VEGF-A isoform determine whether they can interact with other membrane proteins (e.g., neuropilin 1; Cébe Suarez et al., 2006; Parker, Xu, Li, & Vander Kooi, 2012; Guo & Vander Kooi, 2015; and extracellular matrix components (Krilleke et al., 2007; Vempati, Popel, & Mac Gabhann, 2014) . This causes isoforms to vary in their bioavailability and signalling outcomes with many isoforms acting as partial agonists relative to VEGF 165 a (Peach, Mignone, et al., 2018) . VEGF-A isoforms also have distinct expression profiles in health and disease, such as down-regulation of VEGF 165 b in numerous cancer types (Bates et al., 2002; PritchardJones et al., 2007) . VEGF-A/VEGFR2 signalling has been targeted by a number of clinically approved inhibitors used to treat cancer, such as receptor TK inhibitors (RTKIs) that target the intracellular ATP-binding domain (Ferrara & Adamis, 2016) .
The development of fluorescence-based technologies has advanced our pharmacological understanding of GPCRs, RTKs, and other classes of membrane proteins (Stoddart, Kilpatrick, & Hill, 2018; Stoddart, White, Nguyen, Hill, & Pfleger, 2016) . For example, real-time ligand binding can be quantified in living cells using BRET (Stoddart et al., 2015; Stoddart et al., 2016) . This proximity-based assay monitors energy transfer between a receptor tagged on its N-terminus with a bright 19-kDa nanoluciferase (NanoLuc) and a suitable fluorophore acceptor. We previously developed fluorescent variants of VEGF 165 a, VEGF 165 b, and VEGF 121 a labelled at a single site with tetramethylrhodamine (TMR; Kilpatrick et al., 2017; . Despite similar affinities, VEGF 165 a-TMR had distinct binding kinetics at VEGFR2 and its coreceptor neuropilin 1 expressed in living HEK293T cells . VEGF 121 a-TMR and VEGF 165 b-TMR were also shown to bind to VEGFR2 but not to neuropilin 1 using both NanoBRET and live-cell fluorescence imaging techniques .
A striking feature of the binding of VEGF 165 a-TMR to VEGFR2 in intact living cells is that the BRET signal obtained with higher concentrations of the fluorescent probe declines over longer incubation times, after reaching a peak between 15 and 20 min (Kilpatrick et al., 2017) . One possible explanation is that this is a consequence of receptor internalisation and uncoupling of ligand-receptor complexes within intracellular endosomes (Kilpatrick et al., 2017) . Due to the complex spatiotemporal dynamics of VEGFR2, kinetic profiles of ligand binding to VEGFR2 in intact living cells are likely to contain components that represent the initial ligand-binding interaction and also components that reflect receptor endocytosis, whereby the endosomal environment can impact upon the stability of these ligand-receptor complexes.
In order to isolate the ligand-binding profiles of fluorescent VEGF-A isoforms to VEGFR2 from the potential influences of agonist-induced receptor endocytosis, the present study was undertaken with VEGF 165 a-TMR, VEGF 165 b-TMR, and VEGF 121 a-TMR to: 
What is already known
• VEGF-A is a key mediator of angiogenesis.
• The binding of VEGF-A to VEGFR2 is not sustained in living cells.
What this study adds
• The power of NanoBRET approaches to study real-time ligand-binding kinetics in membranes and cells.
• Fluorescent VEGF-A isoforms produced a rapid and potent translocation of ligand-bound VEGFR2 into intracellular endosomes.
• Endocytosis shortens agonist residence times as VEGFR2 moves from the plasma membrane to intracellular endosomes.
What is the clinical significance
• New insights into the impact of cellular location on the kinetics of VEGFR2 ligand-receptor interactions.
2 | METHODS 2.1 | Cell culture and materials HEK293T cells (CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063) were maintained at 37°C/5% CO 2 in DMEM (Sigma-Aldrich, USA) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich, USA).
At 70-80% confluency, cells were passaged using PBS (Lonza, Switzerland) and trypsin (0.25% w/v in versene; Lonza). Stable cell lines expressing VEGFR2 were generated using FuGENE HD (Promega Corporation, USA) at a 3:1 ratio of reagent to cDNA. As described previously by , N-terminal NanoLuc-tagged VEGFR2 (NM_002253) was cloned into a pFN31K vector encoding the secretory IL-6 signal peptide fused to the N-terminus of NanoLuc, followed by a GSSGAIA linker before the receptor. Additionally, VEGFR2 was cloned into a pFN21A vector with the IL-6 signal peptide followed by a sequence encoding HaloTag and an EPTTEDLYFQSDNAIA linker at the receptor N-terminus, as described in . Fluorescent VEGF 165 a, VEGF 165 b, and VEGF 121 a were labelled at a single N-terminal cysteine residue with TMR using the HaloTag mammalian protein detection and purification system (G6795; Promega Corporation, USA) as described previously (Kilpatrick et al., 2017; .
Fluorescent ligands were characterised in terms of labelling efficiency, dimerisation, and function as described in Kilpatrick et al. (2017) and . Binding affinities of fluorescent VEGF isoforms are approximately an order of magnitude lower than those of their native counterparts . Ligands were stored at −20°C in 2.5 mg·ml −1 protease-free BSA (Millipore, USA). Cediranib was purchased from Sequoia Research Products (Pangbourne, UK), and unlabelled recombinant human VEGF isoforms were purchased from R&D Systems (Abingdon, UK). Furimazine was bought from Promega Corporation (Madison, USA), and other tissue culture reagents were purchased from Sigma-Aldrich (Gillingham, UK).
2.2 | Generation of a tyrosine phosphorylation-deficient variant of HaloTag-VEGFR2 and NanoLuc-VEGFR2
To generate tyrosine phosphorylation-deficient (VEGFR2-TPD) variants, site-directed mutagenesis was performed for HaloTag-VEGFR2 and NanoLuc-VEGFR2 using the following forward and reverse complementary primers for mutations: Y951F (Fwd 5′-GTCAAGGGAAAGACTtCGTTGGAGCAATCCC-3′; Rev 5′-GGGATTGCTCC AACGaAGTCTTTCCCTTGAC-3′), Y1175F (Fwd 5′-GCAGGATGGCA AAGACTtCATTGTTCTTCCGATATC-3′; Rev 5′-GATATCGGAAGAAC AATGaAGTCTTTGCCATCCTGC-3′), Y1214F (Fwd 5′-GTGACCCCA AATTCCATTtTGACAACACAGCAGGAATC-3′; Rev 5′-GATTCCTGC TGTGTTGTCAaAATGGAATTTGGGGTCAC-3′), and Y1054F (Fwd 5′-GCTTGGCCCGGGATATTTtTAAAGATCCAGATTATGTC-3′; Rev 5′-GACATAATCTGGATCTTTAaAAATATCCCGGGCCAAGC-3′), and Y1059F was prepared after the Y1054F mutation had been incorporated (shown in bold below; Fwd 5′-GATATTTTTAAAGATCC AGATTtTGTCAGAAAAGGAGATGCTCGC-3′; Rev 5′-GCGAGCATC TCCTTTTCTGACAaAATCTGGATCTTTAAAAATATC-3′).
The altered nucleotides are shown in lower case. Mutagenesis was performed sequentially with the above primers to generate the Y951F, Y1054, Y1059F, Y1175F, and Y1214F tyrosine phosphorylationdeficient mutant of VEGFR2 (VEGFR2-TPD; Figure 4d ) using Pfu DNA polymerase (Promega Corporation, USA), followed by sequencing of the full plasmid to check for off-target SNPs. All HEK293T cells also stably expressed a Firefly luciferase reporter downstream of an NFAT response element to monitor NFAT-induced gene transcription (NFAT-RE-luc2P; Promega Corporation, USA), as in Carter, Wheal, Hill, and Woolard (2015) .
| Membrane preparations
HEK293T cells stably expressing wild-type or tyrosine phosphorylation-deficient NanoLuc-VEGFR2 were grown in DMEM/10% FCS to 80-90% confluency in 148-mm 2 culture dishes (Corning, USA). The media was then replaced with PBS, cells were removed from the dish by scraping and then transferred into a 50-ml tube. Cells were centrifuged at 378 × g for 12 min at 4°C, the supernatant was removed, and the remaining pellet was stored at −80°C.
Thawed pellets resuspended in PBS were homogenised using an electronic handheld IKA T10 Ultra Turrax homogeniser in 10 × 3 s bursts at 15,000 rpm. Unbroken cells and nuclei were removed by centrifugation at 1,500 × g for 20 min (4°C). The supernatant was then centrifuged at 41,415 × g for 30 min at 4°C to pellet the remaining membranes. The pellet was resuspended in 1-ml PBS, transferred to a borosilicate glass homogeniser mortar, and homogenised 15 times using an IKA RW16 overhead stirrer attached to a serrated pestle (Kartell) at 1,000 rpm. Protein concentration was determined using a bicinchoninic acid assay (Pierce™ BCA Protein Assay; Thermo Fisher Scientific), and absorbance was measured using a Dynex Technologies 4.25 platereader. Membrane preparations were stored at −80°C, and retained their luminescence emissions following addition of furimazine and their ability to bind VEGF-TMR for at least 10 months. Plates were imaged at four sites per well using a 20× ELWD (extra long working distance) objective, with a TRITC filter to image VEGF xxx x-TMR (560-nm excitation, 607-to 634-nm emission, and 2,000-ms exposure time) and a DAPI filter for nuclei (405-nm excitation, 447-to 460-nm emission, and 25-ms exposure time). Images were analysed using a granularity algorithm (Molecular Devices), whereby nuclei were identified based upon their size (5-to 25-μm diameter) and pixel depth in grey levels, which was kept consistent between experimental replicates. A nuclear mask defining cell nuclei was then placed over the nuclei within the acquired image forming the basis for automated image segmentation. Fluorescent granules were defined based upon size (2-to 15-μm diameter) and pixel depth in grey levels. Granules were then assigned to specific nuclei based upon proximity using the aforementioned segmented image.
| Measuring ligand binding using NanoBRET

| Immunofluorescent labelling of Rab5
HEK293T cells stably expressing wild-type or tyrosine phosphorylation-deficient HaloTag-VEGFR2 were seeded at 300,000 Representative confocal images were processed using ImageJ 
where B max is the maximal specific binding, were shared across all data sets.
Binding affinities (K i ) of the unlabelled ligands were calculated using the Cheng-Prusoff equation: 
Residence time was calculated as the reciprocal of k off . Kinetically determined K D values were calculated from these kinetic parameters using the following equation:
For VEGF 165 a-TMR concentration-response curves for internalisation of ligand-VEGFR2 complexes, the mean granule number per cell was calculated from four images per well. Data are expressed as a percentage of the responses obtained using 100-nM VEGF 165 a-TMR (100%) or vehicle (0%). Data were fitted using non-linear least squares regression using GraphPad Prism with the following equation:
where E max is the maximal response and EC 50 is the concentration of agonist required to produce 50% of the maximum response.
The kinetic data for receptor internalisation were fitted to the following mono-exponential association function:
where Y max equals the level of receptor internalisation at infinite time, t is the time of incubation, and k obs is the rate constant for the observed rate of receptor internalisation.
Statistical analyses of differences between Mander's overlap coefficients obtained at 5 and 60 min were performed using an unpaired non-parametric Mann-Whitney test. Statistical analysis of the difference of the Mander's overlap coefficient obtained from zero were performed using a Wilcoxon signed-rank test. Statistical analysis of differences between fitted kinetic ligand-binding parameters, in the presence and absence of cediranib, was performed using a paired t test.
AUC analysis (GraphPad Prism 7.02) was used to determine the effect of cediranib on NanoBRET ligand-binding times courses (Figure 4 
| Agonist-mediated internalisation of VEGFR2 in HEK293T cells
We have previously suggested that the fall in the VEGFR2-associated NanoBRET signal observed with VEGF 165 a-TMR over longer incubations periods is a consequence of VEGFR2 internalisation and the dissociation of VEGF 165 a-TMR from its receptor within intracellular endosomes (Kilpatrick et al., 2017) . To look into the timecourse and and Table 1 ). In the presence of 10 nM of VEGF 165 a-TMR, VEGF 165 b-TMR, or VEGF 121 a-TMR, the appearance of ligand-bound VEGFR2 in endosomes was rapid with a t 1/2 of between 15 and 20 min ( Figure 2d and Table 1 ).
| Presence of VEGF-TMR and VEGFR2 in Rab5+ endosomes
Immunofluorescent labelling of Rab5 in fixed cells was used to confirm whether VEGF-TMR and VEGFR2 complexes were localised in early Rab5-positive endosomes, using confocal microscopy for enhanced axial resolution (z) compared with high-content widefield imaging in Figure 2 . As a representative VEGF-TMR ligand, 10-nM VEGF 121 a-TMR was significantly colocalised with Rab5 (P < .05; Wilcoxon signed-rank test; Figure 3a ,b) at both intracellular sites and regions of the plasma membrane by 5 min, whereas it was largely intracellular by 60 min (Figure 3a,b) . This was accompanied by increased colocalisation with Rab5 at 60 min (Figure 3b ; P < .05; Mann-Whitney test, n = 64 cells and n = 68 cells for 5-and 60-min stimulation, respectively). HaloTag-VEGFR2 labelled with a membrane-impermeable dye was significantly (P < .05) colocalised with Rab5 at 5 min (Figure 3a,c) .
At 60 min, there was a small decrease in colocalisation of Rab5 with
HaloTag-VEGFR2 compared with 5 min (Figure 3c ; Mann-Whitney test, P < .05; n = 64 for 5 min and n = 68 for 60 min), which is consistent with some recycling of VEGFR2 back to the plasma membrane previously observed by Kilpatrick et al. (2017) .
| Influence of VEGFR2 phosphorylation on ligand binding in intact cells
Addition of the RTKI cediranib (1 μM), pre-incubated for 30 min, produced a significant elevation in the NanoBRET signal at both 5-and 20-nM VEGF 165 b-TMR relative to the DMSO control (Figure 4a-c; P < .05, two-way ANOVA of every time point, n = 5). This elevation was similar to that reported previously with an endpoint NanoBRET binding timecourse for VEGF 165 a-TMR (Kilpatrick et al., 2017) . However, as also noted by Kilpatrick et al. (2017) , the binding profile of 20-nM VEGF 165 b-TMR continued to decline in the presence of cediranib following the peak at 20 min when monitored continuously using real-time NanoBRET measurements (Figure 4c ).
To explore the influence of receptor phosphorylation further, we generated a tyrosine phosphorylation-deficient VEGFR2 (VEGFR2-TPD) where key intracellular phosphotyrosine residues were mutated to phenylalanine (Y951F, Y1054F, Y1059F, Y1175F, and Y1214F; Figure 4d ). Receptors were labelled with membrane-impermeant HaloTag-Alexa Fluor 647, and this confirmed the plasma membrane expression of this VEGFR2 variant (Figure 4e ). However, VEGF 121 a-TMR and VEGFR2-TPD were also localised to intracellular Rab5+ sites following a 60-min incubation. Using the same cell line as those for imaging experiments, the tyrosine phosphorylationdeficient VEGFR2 was unable to signal through NFAT in response to increasing concentrations of VEGF 165 a in comparison with wildtype VEGFR2 (pEC 50 = 9.92 ± 0.12; Figure 4f ). In intact cells, there was a significant elevation (P < .05) in NanoBRET signal with both 3-and 20-nM VEGF 121 a-TMR (Figure 4g ,h; n = 8). It was notable that there was also a decline in the NanoBRET signal in VEGFR2-TPD Following 5 min pretreatment with NanoLuc substrate furimazine, ligand was added (x = 0) at both a saturating (20 nM) concentration of fluorescent ligand and a concentration that was approximately equal to its K D value (3 nM). BRET ratios were calculated every 30 s at 37°C using the PHERAstar FS platereader. Data were baseline corrected to vehicle to adjust for background emissions. Data are shown as mean ± SEM from five independent experiments with duplicate wells after the initial peak at 20 min. Both wild-type and tyrosine phosphorylation-deficient NanoLuc-VEGFR2 receptors were expressed at the same level, as determined by the NanoLuc luminescence emissions (data not shown).
| NanoBRET ligand binding in membrane preparations
To determine the influence of membrane concentrations on NanoBRET ligand binding in membranes prepared from NanoLuc-FIGURE 2 Quantifying endocytosis of VEGF 165 a-TMR, VEGF 165 b-TMR, and VEGF 121 a-TMR ligand-receptor complexes using high-content imaging. (a) HEK293T cells expressing NanoLuc-VEGFR2 were stimulated with 10-nM fluorescent VEGF 165 a-TMR (60 min, 37°C). Cells were fixed and incubated with nuclear stain (H33342). The following day, cells were imaged with an ImageXpress Micro widefield platereader (20× ELWD objective; four sites per well) using filter settings for TRITC (left; VEGF 165 a-TMR) and DAPI (middle; nuclei). Images were analysed using a granularity algorithm (Molecular Devices) whereby nuclei stained with H33342 (blue, middle panel) were identified based upon their size (5-to 25-μm diameter) and pixel depth in grey levels. A nuclear mask defining cell nuclei was then placed over the nuclei within the acquired image (right panel; green spots), forming the basis for automated image segmentation. Fluorescent granules detected in the TRITC channel (right; white spots) were defined based upon size (2-to 15-μm diameter) and pixel depth in grey levels. Granules were then assigned to specific nuclei based upon proximity using the aforementioned segmented image. Scale bars represent 20 μm. (b) To confirm receptor specificity, non-transfected wild-type HEK293T cells or stably expressing HaloTag-VEGFR2 cells were stimulated with 10-nM VEGF 165 a-TMR (n = 5), VEGF 165 b-TMR (n = 5), or VEGF 121 a-TMR (n = 5) for 60 min (37°C). Cells were fixed, stained, and imaged, as in (a). Data were normalised to mean vehicle (0%) or VEGF 121 a-TMR stimulation (100%) in HaloTag-VEGFR2 cells per experiment. (c) Cells were stimulated with increasing concentrations of fluorescent VEGF-A variants (60 min, 37°C). Data were normalised to mean vehicle (0%) and 100-nM VEGF 165 a-TMR-stimulated response (100%) per experiment. Cells were fixed, stained, and imaged as above. (d) Timecourse of internalisation of VEGF-TMR complexes, whereby NanoLuc-VEGFR2 cells were stimulated with 10-nM VEGF 165 a-TMR, VEGF 165 b-TMR, or VEGF 121 a-TMR for 0-120 min at 37°C. Cells were fixed, stained, and imaged as above and then normalised to vehicle (0%) and 60-min VEGF 165 a-TMR stimulation (100%) per experiment. Data from (b-d) are expressed as mean ± SEM and pooled from five independent experiments unless stated otherwise with duplicate wells imaged at four sites per well Table 2 were similar to those previously reported for these three ligands in intact cells, where the kinetic analysis was limited to the first 20 min of agonist stimulation .
Membrane kinetic experiments were also repeated in the presence of the RTKI cediranib (Table 3 ). There was a significant decrease in k off in membrane preparations when compared with cells (Table 3) , but the k off values were not altered by cediranib treatment. There was a small significant decrease in the k on value for (Table 3) . To quantify the kinetics of binding at the tyrosine phosphorylation-deficient NanoLuc-VEGFR2 using membrane preparations, a stable cell line was generated. Kinetic parameters of Following cell fixation and permeabilization, Rab5-positive endosomes were labelled with a monoclonal rabbit antibody and secondary chick antirabbit Alexa Fluor 488. Cells were imaged using a Zeiss LSM880F Confocal (63× oil objective) with representative images from five independent experiments. Scale bars show 20 μm. (f) NFAT luciferase production in response to 5-hr stimulation with increasing concentrations of VEGF 165 a. Stable cell lines were then used for Rab5+ confocal imaging figures to confirm cell surface expression. Data are shown as mean ± SEM from five independent experiments in duplicate wells, expressed as a percentage of response per experiment to 10-nM VEGF 165 a at wild-type HaloTag-VEGFR2 (100%) or respective vehicle (0%). (g, h) Time course of VEGF 121 a-TMR binding to tyrosine phosphorylation-deficient NanoLuc-VEGFR2 expressed transiently in HEK293T cells. Cells were pretreated with furimazine for 5 min, and then (g) 3-or (h) 20-nM ligand was added (x = 0). BRET ratios were monitored every 30 s at 37°C and baseline corrected to vehicle. Data are expressed as mean ± SEM from eight independent experiments with duplicate wells. AUC analysis provided the following areas (mean ± SEM): (g) 2.61 ± 0.06 and 3.54 ± 0.07* and (h) 7.28 ± 0.10 and 9.79 ± 0.11*, for wild-type VEGFR2 and VEGFR2-TPD cells respectively. *P < .05 significant difference between VEGFR2 and VEGFR2-TPD cells (two-way ANOVA of every time point)
VEGF 121 a-TMR in VEGFR2-TPD membranes (Table 3) were similar to control VEGF 121 a-TMR kinetic parameters derived in wild-type VEGFR2 membranes (Tables 2 and 3 ).
Taking advantage of our binding assay in membrane preparations, we investigated the effect of an acidic pH on ligand-receptor binding to reflect early endosomes (pH 6.0) compared with physiological Note. Values in membrane preparations are mean ± SEM (n = 5) derived from experiments shown in Figure 7 using five concentrations of fluorescent ligand. Values in intact cells are taken from . K D values shown are the kinetically derived values (k off /k on ).
et al., 2017). We have previously reported all three fluorescent VEGF-A isoforms bind with nanomolar affinity to VEGFR2 (Kilpatrick et al., 2017; . followed by subsequent recycling of ligand-free VEGFR2 back to the plasma membrane (Kilpatrick et al., 2017) . Published studies in primary endothelial cells using immunofluorescence antibody labelling or biochemical techniques agreed that VEGFR2 internalised within 30-60 min of VEGF-A stimulation (Bruns et al., 2010; Ewan et al., 2006; Jopling et al., 2009 ).
To determine the agonist potency (EC 50 values) and kinetic profile of agonist-induced VEGFR2 endocytosis, we monitored the appearance of fluorescent ligand-associated receptors in intracellular endosomes using high-content quantitative imaging. This approach was able to quantify the internalisation of VEGF-A ligand isoforms independently of the known constitutive endocytosis of VEGFR2 (Basagiannis et al., 2016; Ewan et al., 2006; Jopling et al., 2009; Jopling et al., 2011) . All three fluorescent VEGF-A isoforms stimu- with VEGF 165 a . However, it is notable that the HEK293T cells used in the present study have minimal expression of the co-receptor neuropilin 1 , whereas human umbilical vein endothelial cells also express the co-receptor neuropilin 1. Neuropilin 1 does not interact with VEGF 121 a (Carter et al., 2015) .
Cediranib (1 μM) produced no significant effect on the kinetic rate constants (k on and k off ) or K D value of VEGF 165 b-TMR determined from binding to VEGFR2 in HEK293T cell membranes. In intact cells, however, cediranib produced a small elevation in the NanoBRET signal similar to that reported previously for VEGF 165 a-TMR (Kilpatrick et al., 2017) . This was accompanied by a small decrease in k on but no significant difference in k off . The combination of these two effects was a small increase in K D (Table 3) . It is also worth emphasising, however, that very small changes in kinetic parameters may also be a consequence of the need to fit association curves for four or more concentrations of fluorescent ligand simultaneously with shared values for k on and k off . To explore further the influence of receptor phosphorylation, we generated a tyrosine phosphorylation-deficient VEGFR2 (VEGFR2-TPD) where key intracellular phosphotyrosine residues were mutated to phenylalanine (Y951F, Y1054F, Y1059F, Y1175F, and Y1214F; Figure 4d ). This mutant form of VEGFR2 was unable to stimulate following a 1-hr incubation were slightly more potent than those previously reported in intact cells (Table 2 ; Kilpatrick et al., 2017; . This was particularly the case for The k on and k off values determined in membrane preparations were of a similar order to those previously reported for these three fluorescent ligands in intact cells when the kinetic analysis was restricted to the first 20 min of agonist stimulation, in order to reduce the influence of receptor endocytosis . k on rate constants were slightly smaller (1.2-fold to 2.0-fold) in membranes than the corresponding values obtained in intact cells. However, k off rate constants were approximately fourfold lower (Table 2 ) than those determined in HEK293T cells, indicative of a slower agonist dissociation rate. In matched experiments ( Figure 6 and Table 3 ), these differences were significant (P < .05). These data suggest that the impact of agonist-induced VEGFR2 endocytosis on kinetically derived Table 3 ). This is consistent with our earlier suggestion that rapid dissociation of VEGF 165 a-TMR from VEGFR2 occurs in the environment of intracellular endosomes (as a consequence of the lower pH or the presence of endosomal proteases) and allows rapid recycling of ligand-free VEGFR2 back to the cell surface (Kilpatrick et al., 2017) . Interestingly, in the tyrosine phosphorylation-deficient VEGFR2-TPD, the kinetic constants determined in membranes for VEGF 121 a-TMR were within a factor of two of those derived in membranes for the wild-type receptor.
The ability to define the pH at which ligand-binding studies are undertaken in membrane preparations provided an opportunity to study the influence of pH on ligand binding at the acidic pH normally found in intracellular endosomes. These data showed that the association and dissociation rate constants of fluorescent VEGF-A at NanoLuc-VEGFR2 were faster at pH 6.0 than those observed at pH 7.4. Indeed, the parameters approached those obtained in intact cells (Table 3 ). These data suggest that a proportion of the ligand-binding characteristics observed in intact cells is a consequence of receptor endocytosis and the influence of the lower pH environment.
In summary, the present study has shown for the first time that
NanoBRET can be used to monitor the kinetics of the binding of fluo- into the impact of cellular location and pH on the kinetics of ligandreceptor interactions for a receptor that is a key mediator of both angiogenesis and vascular permeability, and an important drug target for the treatment of cancer.
